Vividion Therapeutics, Inc. (VVID)

Vividion Therapeutics was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)43.17M
Net Income (ttm)-25.31M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VVID

Vividion Therapeutics is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for cancers and immune disorders. Despite advances in genomics, structural biology and high-throughput screening, about 90% of disease-causing proteins cannot be targeted by current therapies due to the lack of a known addressable binding site. Our proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows ...

IndustryPharmaceutical Preparations
Founded2013
CEOJeffrey S. Hatfield
Employees108
Stock ExchangeNASDAQ
Ticker SymbolVVID
Full Company Profile

Financial Performance

In 2020, VVID's revenue was $34.39 million, an increase of 44.81% compared to the previous year's $23.75 million. Losses were -$25.46 million, 46.0% more than in 2019.

Financial Statements

News

Vividion Therapeutics IPO Registration Document (S-1)

Vividion Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

10 months ago - SEC

Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancer...

10 months ago - Business Wire